Page results
-
Mr George Attilakos is a consultant in obstetrics and fetal medicine and the clinical lead for obstetrics at UCLH. Alongside managing normal pregnancies, Mr Attilakos has a special interest in the management of multiple pregnancies and high-risk pregnancies, as well as expertise in fetal medicine and fetal surgery, including in-utero treatment for congenital diaphragmatic hernia, spina bifida and twin-to-twin transfusion syndrome.
-
This booklet tells you about having a Vortex® Port-a-cath Insertion (implantable port) with the Interventional Radiology team.
-
Temporary change to HIV confirmation pathway due to Bio-Rad kit supply issues
-
This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Interventional Radiology team.
-
This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
This page is for patients over 18 years old. It may also be useful to family, friends and carers. This page explains: treatment Escalation Plans (TEP) cardiopulmonary Resuscitation (CPR) how…
File results
-
FOI/2024/0097 - Laboratory Information Management System (LIMS)/ pathology IT system
-
FOI/2024/0101 - Immunoglobulin drug treatments
-
FOI/2024/0108 - Clinical letters/ EPR, PAS, patient portal systems, hybrid mail contract
-
FOI/2024/0112 - Fertility treatment in 2021
-
FOI/2024/0116 - Patient treatment due to noise levels of the London Underground
-
FOI/2024/0121 - Migraine treatments
-
FOI/2024/0126 - Ophthalmology RTT pathway
-
FOI/2024/0128 - Post mortem cardiac device interrogation
-
FOI/2024/0129 - Nursing associate and anaesthesia associate staffing
-
FOI/2024/0131 - Alpha-1 Proteinase-Inhibitor (AAT) purchased in 2023